ACRSAclaris Therapeutics, Inc.
$3.78+105% 1Y
$3.78
$1.8152 weeks$6.54
ACRS in its own filings
ACRS's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
239
Events found in the filings · across 867 filings · the record starts in 2015
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 29, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Delisting notice / listing-rule failurehistorical
- 2017-11-09
- SEC comment-letter activity16 occurrences
- 2025-03-05
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”) under which the Company may offer and sell, from time to time at the Company’s sole …Material agreement entered · Form 8-K
- Aug 6, 2026Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update.Earnings release · press release
- May 7, 2026Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update.Earnings release · press release
- Apr 28, 2026On April 28, 2026, the Company issued a press release announcing the ATI-052 Results & ATI-2138 Trial.Regulation FD disclosure · Form 8-K
- Feb 26, 2026Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Jan 12, 2026Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private.Regulation FD disclosure · press release
- Jan 6, 2026Interim Phase 1a SAD/MAD Results The Interim Results announced in the press release are summarized below.Regulation FD disclosure · Form 8-K
- Nov 6, 2025Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Oct 14, 2025Patient Focused Innovation.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…